New pathogenic paradigms in inflammatory bowel disease

Antonio Di Sabatino; Paolo Biancheri; Laura Rovedatti; Thomas T MacDonald; Gino R Corazza

doi:10.1002/ibd.21735

New pathogenic paradigms in inflammatory bowel disease

Antonio Di Sabatino, Paolo Biancheri, Laura Rovedatti, Thomas T MacDonald, Gino R Corazza

Research output: Contribution to journal › Review article › peer-review

72 Citations (Scopus)

Abstract

Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

Original language	English
Pages (from-to)	368-371
Number of pages	4
Journal	Inflammatory Bowel Diseases
Volume	18
Issue number	2
Early online date	27 Apr 2011
DOIs	https://doi.org/10.1002/ibd.21735
Publication status	Published - 1 Feb 2012

Keywords

Adaptive Immunity
Humans
Immune Tolerance
Immunity, Innate
Immunity, Mucosal
Inflammatory Bowel Diseases/immunology
Interleukin-17/immunology
Interleukin-23/immunology
Th1 Cells/immunology
Th17 Cells/immunology
Th2 Cells/immunology

Access to Document

10.1002/ibd.21735

Cite this

@article{ab83de1753114580b83a5f6e3dd00f04,

title = "New pathogenic paradigms in inflammatory bowel disease",

abstract = "Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer {"}static{"} but {"}dynamic{"} vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.",

keywords = "Adaptive Immunity, Humans, Immune Tolerance, Immunity, Innate, Immunity, Mucosal, Inflammatory Bowel Diseases/immunology, Interleukin-17/immunology, Interleukin-23/immunology, Th1 Cells/immunology, Th17 Cells/immunology, Th2 Cells/immunology",

author = "{Di Sabatino}, Antonio and Paolo Biancheri and Laura Rovedatti and MacDonald, {Thomas T} and Corazza, {Gino R}",

note = "Copyright {\textcopyright} 2011 Crohn's & Colitis Foundation of America, Inc.",

year = "2012",

month = feb,

day = "1",

doi = "10.1002/ibd.21735",

language = "English",

volume = "18",

pages = "368--371",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - New pathogenic paradigms in inflammatory bowel disease

AU - Di Sabatino, Antonio

AU - Biancheri, Paolo

AU - Rovedatti, Laura

AU - MacDonald, Thomas T

AU - Corazza, Gino R

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

AB - Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

KW - Adaptive Immunity

KW - Humans

KW - Immune Tolerance

KW - Immunity, Innate

KW - Immunity, Mucosal

KW - Inflammatory Bowel Diseases/immunology

KW - Interleukin-17/immunology

KW - Interleukin-23/immunology

KW - Th1 Cells/immunology

KW - Th17 Cells/immunology

KW - Th2 Cells/immunology

U2 - 10.1002/ibd.21735

DO - 10.1002/ibd.21735

M3 - Review article

C2 - 21538717

VL - 18

SP - 368

EP - 371

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -